A leader from the healthcare technology company discusses the conflict’s impact on the region and beyond and the need to better guard against interruptions.
The company’s analysis of clinical research activity in the region shows the conflict will have long-lasting effects that reach beyond the country’s borders.
Slovakian contract manufacturer Saneca says the opportunity to tap the Russian market is huge despite protectionist policies and changing GMP inspection requirements.
Marken’s Moscow-based depot has been granted a new pharmaceutical license from the Russian Federation, further extending the company’s capabilities in the area.
Vladimir Putin says support from Russian business community is needed to help achieve the domestic drug manufacturing goals set out in his Pharma 2020 policy.
Several international CMOs will establish themselves in Russia over the next few years as pharma looks to satisfy the country's manufacturing policies, the CEO of R-Pharm predicts.
Marken on Wednesday announced its pharma depot network is expanding to Russia to meet the growing needs of clients looking to store materials for clinical trials there and in Eastern Europe.
International GMP standard facilities and six biopharma centres will lead Russia’s initiative in implementing its Pharma 2020 policy, according to statements at this year’s BIO International Convention.
Detailed market knowledge and an experienced CMO are still critical to successfully developing a biopharmaceutical or biosimilar according to Cobra Biologics.
Primary packaging maker Schott has joined the growing list of drug industry companies seeking to tap Russian government demand for increased domestic manufacturing.
Indian drugmaker Dr Reddy’s Laboratories has formed a manufacturing partnership with R-Pharm in a bid to strengthen its position in Russia’s fast-growing drug market.
Novartis will build a new $500m (€379.9m) pharmaceutical manufacturing plant in St Petersburg, Russia after signing a Memorandum of Understanding (MoU) with the city.
Investors are funding the creation of a RUB1.6bn ($52m), 10,000 sq m preclinical Russian CRO to fill the gap in the nation’s development chain and undercut western prices by 40 per cent.
The USP is strengthening links with Eastern Europe and Russia by agreeing to share quality standards with Ukraine and offering training courses in Moscow.
Russia, the Ukraine and Belarus have emerged as destinations for clinical studies and now offer “enormous” potential according to US-based CRO ClinStar.
Sanofi-Aventis plans to participate with a Russian state-owned corporation in a project to attract innovative drug manufacturers to the country, using its insulin facility as a pilot initiative.
ChemDiv’s subsidiary Chemical Diversity Research Institute (CDRI), based in Moscow, Russia, will carry out development work on a range of HIV antivirals on behalf of new drugmaker Viriom.
LGC Standards has made the “next logical step” in its “concerted effort” to expand internationally by opening an office in St Petersburg, Russia, less than six months after it moved into China.
The number of registered clinical trials in Russia slipped in Q2, with the country attracting fewer international sponsors and regulatory inspections than in pervious years.
The USP and Roszdravnadzor, a Russian public health body, are collaborating in an attempt to improve the standards of ingredients and finished products and reduce the availability of counterfeits.
Russia has witnessed a drop in generating new business activity on
the clinical trials scene over the past year, but has been
increasing its own activity in this field.
Chiltern has become the latest in a growing number of contract
research organisations (CROs) to establish a foothold within the
clinical sleeping giant that is Russia.
Hungarian pharma Gedeon Richter has announced plans to combine with
Polish firm Polpharma to create a major presence in Central Eastern
Europe (CEE) through a share deal worth HUF231bn ($1.3bn).
Russian contract research organisation (CRO) Synergy Research Group
has hooked up with a US-based CRO in a bid to expand its services
to North America.
Just as the clinical trials sector in Russia is
starting to take off, the industry has been dealt a severe
blow with the sudden and indefinite banning of biological sample
exports.
Hesperion has opened a Russian arm of its contract research
business in a bid to 'increase its attractiveness' to clinical
trial sponsors requiring large patient populations.
In Russia, the Health Ministry suspended the licences of 321
companies manufacturing or trading in counterfeit medicines last
year, and a further 200 may also lose their licences following
ongoing investigations, according to the...
